ArticleEuropean journal of pediatrics2008
The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
Article in European journal of pediatrics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 4 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Neurological involvement in children with familial Mediterranean fever: a systematic review.Pediatric rheumatology online journal · 2025Pooled it
- Interventions for reducing inflammation in familial Mediterranean fever.The Cochrane database of systematic reviews · 2022Pooled it
- Interventions for reducing inflammation in familial Mediterranean fever.The Cochrane database of systematic reviews · 2018Pooled it
- [Recommendations on therapy using interleukin-1beta-blocking agents].Zeitschrift fur Rheumatologie · 2009Guideline
- Familial Mediterranean Fever (FMF): Emerging Concepts in Diagnosis, Pain Management, and Novel Treatment Options: A Narrative Review.Current pain and headache reports · 2025Review
- Nanobodies dismantle post-pyroptotic ASC specks and counteract inflammation in vivo.EMBO molecular medicine · 2022Article
- Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review.Frontiers in immunology · 2021Review
- 4,4'-Diaminodiphenyl Sulfone (DDS) as an Inflammasome Competitor.International journal of molecular sciences · 2020Article
- The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.Frontiers in immunology · 2020Review
- The off-label use of anakinra in pediatric systemic autoinflammatory diseases.Therapeutic advances in musculoskeletal disease · 2020Review
- Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).Orphanet journal of rare diseases · 2019Review
- Inflammasome-Dependent Cytokines at the Crossroads of Health and Autoinflammatory Disease.Cold Spring Harbor perspectives in biology · 2019Review
- The role of interleukin-1 in general pathology.Inflammation and regeneration · 2019Review
- Familial Mediterranean Fever: Recent Developments in Pathogenesis and New Recommendations for Management.Frontiers in immunology · 2017Review
- Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases.Frontiers in pharmacology · 2017Review
- Familial Mediterranean Fever developing in a Japanese kidney transplant recipient.CEN case reports · 2016Article
- The Use of IL-1 Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis: A Narrative Review.Cardiology research and practice · 2016Review
- Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature.Biologics : targets & therapy · 2016Article
- Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives.Mediators of inflammation · 2015Review
- An expanding role for interleukin-1 blockade from gout to cancer.Molecular medicine (Cambridge, Mass.) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5-10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile neurological cutaneous and articular (CINCA) syndrome] and other recurrent hereditary periodic fevers. Pyrin--the protein involved in FMF--has a role in activating the proinflammatory cytokine interleukin (IL)-1beta. We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to colchicine in controlling the febrile attacks and acute phase response in an adolescent with FMF resistant to colchicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.